INTRODUCTION

Despite
its initial enthusiasm and optimism (McDowell, et al., 1970) , levodopa treatment of parkinsonism is not without problems especially when the patients are placed on long-term treatment (Ambani and Van Woert, 1973 ; Fahn, 1974 ; Sweet and McDowell, 1974, 1975) . Even in the short-term treatment, although the vast majority of parkinsonians are benefited by lovodopa treatment, there still remain quite a few patients who cannot enjoy this beneficial effects of levodopa simply because of intolerance to this medication (McDowell et al., 1970) . Various modifications in the way of administration of levodopa have been tried in order to eliminate these long-term and short-term side effects (Sweet and Mc Dowell, 1974) .
These include careful reduction of dose of levodopa and administration of levodopa combined with peripheral decarboxylase inhibitor (Sweet and McDowell, 1974 were more likely to be hyperkinetic when plasma levels of dopa were rising or higher than 10 01 and akinetic with falling levels or levels less than 9 ,uM (Fahn, 1974) , however, this relationship was not diffinite (Sweet and McDowell, 1974) . No correlation was found with plasma levels of HVA, OMD or 5HIAA (Sweet and McDowell, 1974) . Sweet and McDowell (1974) suggested that at least part of the problem may lie peripheral to the brain, i. e., absorption from gut, metabolism in the liver or sequestration in sites unknown (Fahn, 1974 
